Pr François Ghiringhelli

Spécialité

Oncologue médical, expert digestif

Hôpital

Centre Georges-François Leclerc (Dijon)

Derniers articles

• Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial. (17 janv. 2025)
• Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model. (9 janv. 2025)
• Factors Influencing the Duration of Maintenance Therapy in Metastatic Colorectal Cancer. (30 déc. 2024)
• Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. (2 déc. 2024)
• Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC. (19 oct. 2024)